An Open Label Phase II Study of Oral Treatment With Sunitinib (Sutent) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen.

Trial Profile

An Open Label Phase II Study of Oral Treatment With Sunitinib (Sutent) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2013

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PROSUT
  • Most Recent Events

    • 17 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jul 2012 Last checked against European Clinical Trials Database record.
    • 24 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top